Asciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis
Küçük Resim Yok
Tarih
2025
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
[No abstract available]
Açıklama
67th Annual Meeting of the American-Society-of-Hematology (ASH) -- DEC 06-09, 2025 -- Orlando, FL
Anahtar Kelimeler
Chronic myeloid leukemia, Asciminib, Tyrosine kinase inhibitors, Major molecular response, grade >3 adverse events
Kaynak
Blood
WoS Q Değeri
Q1
Scopus Q Değeri
Cilt
146
